Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Observational Study

Randomized Controlled Trial

Multicenter Study

Review

Clinical Trial, Phase III

Comparative Study

Systematic Review

Case Reports

Clinical Trial, Phase I

Network Meta-Analysis

Research Support, N.I.H., Extramural

Publication Year

From

Quick links

Individual year

2025

2023

2020

2019

2018

2017

2016

2015

2014

2013

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Rilpivirine""[mesh_terms]

24 Results

Searching titles within these results

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting.

Paolo Maggi, Elena Delfina Ricci, Canio Vito Martinelli, Giuseppe Vittorio De Socio, Nicola Squillace, Chiara Molteni, Addolorata Masiello, Giancarlo Orofino, Barbara Menzaghi, Rita Bellagamba, Francesca Vichi, Benedetto Maurizio Celesia, Giordano Madeddu, Giovanni Francesco Pellicanò, Maria Aurora Carleo, Antonio Cascio, Andrea Parisini, Lucia Taramasso, Laura Valsecchi, Leonardo Calza, Stefano Rusconi, Eleonora Sarchi, Salvatore Martini, Olivia Bargiacchi, Katia Falasca, Giovanni Cenderello, Sergio Ferrara, Antonio Di Biagio, Paolo Bonfanti

Viruses 2023;15(7):1612

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Rilpivirine""[mesh_terms]

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting.

Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.

Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.

Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.

Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.

A randomized, controlled trial of the effect of rilpivirine versus efavirenz on cardiovascular risk in healthy volunteers.

Negative Regulation of Human Pregnane X Receptor by MicroRNA-18a-5p: Evidence for Suppression of MicroRNA-18a-5p Expression by Rifampin and Rilpivirine.

CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation.

Efficacy and Safety of Cabotegravir-Rilpivirine in PLWH: A Real-World Study.

Switching protease inhibitors to rilpivirine in HIV-positive individuals with complete viral suppression and without prior HIV drug resistance in a resource-limited setting: a randomized controlled trial.

Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.

Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.

Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.

Results for
""Rilpivirine""[mesh_terms]